Interferon Blocker Disappoints in SLE
MedPage Today reported on a study that found that the medication anifrolumab failed to reduce symptoms in lupus patients during a phase III trial.
HSS physician-in-chief and chief of Rheumatology Mary K. Crow, MD, who was not involved in the study, commented on its findings.
"I can say that there is an extremely deep disappointment -- and surprise -- among lupus investigators, the nonprofit organizations that support lupus research, and I'm sure also among patients," said Dr. Crow.
"While there can never be certainty that any clinical trial will be successful, based on the very strong data in the phase II study, there was broad optimism that this trial would be successful. I sincerely hope the biotech and pharmaceutical industry will continue to pursue drug development in SLE," she added.
Read the full article at medpagetoday.com.
Additional Coverage:
